Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$44.17

-1.15 (-2.54%)

07:38
02/20/19
02/20
07:38
02/20/19
07:38

Biohaven Pharmaceutical enrolls first patient in Phase 3 trial of troriluzole

Biohaven Pharmaceutical announced that it has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder. Biohaven expects to enroll approximately 372 patients in this randomized, double-blind, placebo-controlled trial across approximately 50 sites in the United States. Researchers will evaluate acute symptomatic treatment with troriluzole in patients with a diagnosis of generalized anxiety disorder. The primary outcome measure is the change in a patient's score on the Hamilton Anxiety Rating Scale, a scale designed to assess the severity and type of symptoms in patients with GAD. The trial will also assess the safety, tolerability and pharmacokinetics of troriluzole.

BHVN Biohaven Pharmaceutical
$44.17

-1.15 (-2.54%)

12/03/18
PIPR
12/03/18
NO CHANGE
Target $65
PIPR
Overweight
Piper says buy Biohaven 'aggressively' after 'impressive' data
Biohaven Pharmaceutical (BHVN) this morning reported "impressive" topline data from the Phase III trial testing the Zydis orally dissolving tablet formulation of rimegepant, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The study not only achieved statistical significance on both co-primary endpoints, "but surprisingly" also demonstrated an "incredibly rapid" 15 minute onset of action, says the analyst. Further, he notes that Biohaven reported pooled safety data from what is now three Phase III rimegepant studies and that the candidate "continues to be safe and well tolerated" with no signal of liver toxicity. Van Buren believes the new data "definitely makes" rimegepant a superior product to Allergan's (AGN) ubrogepant and the "best-in-class" oral calcitonin gene-related peptide. He reiterates an Overweight rating on Biohaven with a $65 price target and recommends that investors buy the stock "aggressively."
12/10/18
PIPR
12/10/18
NO CHANGE
Target $65
PIPR
Overweight
Biohaven's rimegepant 'definitively' safe, well tolerated, says Piper Jaffray
Biohaven Pharmaceutical this morning reported positive data from a 12-month safety study of 1,780 patients, which included regularly scheduled liver function tests, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The bottom line is that rimegepant now definitively appears to be a safe and well-tolerated treatment and that Biohaven has successfully engineered out the liver toxicity associated with the first generation oral calcitonin gene-related peptides, says the analyst. He adds rimegepant also demonstrated efficacy in prevention, which he thinks bodes well for the ongoing pivotal trial. Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical with a $65 price target.
12/28/18
OPCO
12/28/18
NO CHANGE
Target $54
OPCO
Outperform
Biohaven price target lowered to $54 from $63 at Oppenheimer
Oppenheimer analyst Esther Rajavelu lowered her price target for Biohaven Pharmaceutical to $54 from $63 while maintaining an Outperform rating on the shares. The analyst updated her model to reflect the company's weighted average cost of capital as well as well as the impact of its $144M equity raise. Rajavelu continues to believe Biohaven's glutamate platform, with two late-stage assets, is "under-the-radar."
02/01/19
PIPR
02/01/19
NO CHANGE
PIPR
Overweight
Amgen acquisition of Alexion could make a lot of sense, says Piper Jaffray
While most investors anticipate Amgen (AMGN) could be shopping for smaller, bolt-on deals amid increased investor and press speculation that it is now an active acquirer, a larger deal with more near-term accretion potential may make more sense, Piper Jaffray analyst Christopher Raymond tells investors in a research note partially titled "Go Big or Go Home?" He thinks a potential Amgen for Alexion Pharmaceuticals (ALXN) deal "could actually make a lot of sense." Even at levels approaching $200 per share for Alexion, Amgen "could make a strong argument for a business combination," says Raymond. Alexion closed yesterday up $1.64 to $122.96. The analyst admits that some "bolt-on deals have been bandied around" by investors that "arguably make sense" for Amgen, including Biohaven Pharmaceutical and Amarin (AMRN). However, none of these options on their own get Amgen "to where they need to be to address the growth challenges of the legacy franchises," Raymond argues. He thinks a better deal for the company may be Alexion, which would bring in a "long-tailed asset" with Soliris/Ultomiris, an area Amgen has already approached with its Soliris biosimilar effort. The analyst's math has the potential deal being accretive next year, growing to 20%-plus accretion by 2024 for Amgen, even at a takeout price approaching $200 per Alexion share. Raymond keeps Overweight ratings on both companies.

TODAY'S FREE FLY STORIES

RKDA

Arcadia Biosciences

$5.29

-0.23 (-4.17%)

05:47
09/23/19
09/23
05:47
09/23/19
05:47
Hot Stocks
Arcadia Biosciences granted U.S. patent for reduced gluten GoodWheat »

Arcadia Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$4.76

-0.1 (-2.06%)

05:38
09/23/19
09/23
05:38
09/23/19
05:38
Hot Stocks
Clovis acquires rights to FAP »

Clovis Oncology has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRV

Travelers

$146.32

-0.69 (-0.47%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Hot Stocks
Travelers receives approval to transfer European business to Dublin »

Travelers announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

DEA

Easterly Government Properties

$20.96

0.02 (0.10%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Initiation
Easterly Government Properties initiated  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TEL

TE Connectivity

$93.21

-1.21 (-1.28%)

05:34
09/23/19
09/23
05:34
09/23/19
05:34
Downgrade
TE Connectivity rating change  »

TE Connectivity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDBY

Swedbank

$0.00

(0.00%)

05:33
09/23/19
09/23
05:33
09/23/19
05:33
Upgrade
Swedbank rating change  »

Swedbank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLOY

EssilorLuxottica

$0.00

(0.00%)

05:32
09/23/19
09/23
05:32
09/23/19
05:32
Upgrade
EssilorLuxottica rating change  »

EssilorLuxottica upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$26.44

-1.06 (-3.85%)

05:30
09/23/19
09/23
05:30
09/23/19
05:30
Upgrade
Chewy rating change  »

Chewy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEXAY

Atos

$0.00

(0.00%)

05:29
09/23/19
09/23
05:29
09/23/19
05:29
Upgrade
Atos rating change  »

Atos upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.80

3.2 (1.36%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Hot Stocks
Biogen says Plegridy, Avonex receive 'positive opinion' from CHMP »

Biogen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACN

Accenture

$192.99

-1.78 (-0.91%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

TELDF

Telefonica Deutschland

$0.00

(0.00%)

05:27
09/23/19
09/23
05:27
09/23/19
05:27
Upgrade
Telefonica Deutschland rating change  »

Telefonica Deutschland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGY

VAALCO Energy

$2.08

0.06 (2.97%)

05:26
09/23/19
09/23
05:26
09/23/19
05:26
Initiation
VAALCO Energy initiated  »

VAALCO Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$11.64

-0.565 (-4.63%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Hot Stocks
PG&E expects to turn off power late Monday in nine CA counties due to fire risk »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Oct

  • 10

    Nov

  • 10

    Nov

  • 07

    Jan

AIBRF

AIB Group

$0.00

(0.00%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Upgrade
AIB Group rating change  »

AIB Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAOFY

Tatneft

$0.00

(0.00%)

05:22
09/23/19
09/23
05:22
09/23/19
05:22
Downgrade
Tatneft rating change  »

Tatneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESYJY

easyJet

$0.00

(0.00%)

05:21
09/23/19
09/23
05:21
09/23/19
05:21
Upgrade
easyJet rating change  »

easyJet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLOWY

Vallourec

$0.00

(0.00%)

05:20
09/23/19
09/23
05:20
09/23/19
05:20
Downgrade
Vallourec rating change  »

Vallourec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:15
09/23/19
09/23
05:15
09/23/19
05:15
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANNSF

Aena

$0.00

(0.00%)

05:14
09/23/19
09/23
05:14
09/23/19
05:14
Downgrade
Aena rating change  »

Aena downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

05:13
09/23/19
09/23
05:13
09/23/19
05:13
Recommendations
Apple analyst commentary  »

Piper survey shows higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

DexCom

$154.45

-0.49 (-0.32%)

, ABT

Abbott

$83.56

0.35 (0.42%)

05:04
09/23/19
09/23
05:04
09/23/19
05:04
Recommendations
DexCom, Abbott analyst commentary  »

DexCom remains a…

DXCM

DexCom

$154.45

-0.49 (-0.32%)

ABT

Abbott

$83.56

0.35 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

  • 13

    Nov

EW

Edwards Lifesciences

$219.56

4.45 (2.07%)

04:58
09/23/19
09/23
04:58
09/23/19
04:58
Initiation
Edwards Lifesciences initiated  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

, HON

Honeywell

$168.42

1.7 (1.02%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Downgrade
Illinois Tool Works, Honeywell rating change  »

Illinois Tool Works…

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

HON

Honeywell

$168.42

1.7 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.